In this work, we aim to address several strategies to improve transdermal drug delivery, such as iontophoresis, sonophoresis, electroporation and micron. We also propose a review of some transdermal patches and their applications in medicine. TDDs (transdermal patches with delayed active substances) are multilayered pharmaceutical preparations that may contain one or more active substances, of which, systemic absorption is achieved through intact skin. The paper also presents new approaches to the controlled release of drugs: niosomes, microemulsions, transfersomes, ethosomes, but also hybrid approaches nanoemulsions and microns. The novelty of this review lies in the presentation of strategies to improve the transdermal administration of drugs, combined with their applications in medicine, in light of pharmaceutical technological developments.

In this study, we focused on innovative approaches to improve drug administration in oral pathology, especially by transmucosal and transdermal pathways. These improvements refer to the type of microneedles used (proposing needles in the saw), to the use of certain enhancers such as essential oils (which, besides the amplifier action, also have intrinsic actions on oral health), to associations of active substances with synergistic action, as well as the use of copolymeric membranes, cemented directly on the tooth. We also propose a review of the principles of release at the level of the oral mucosa and of the main release systems used in oral pathology. Controlled failure systems applicable in oral pathology include the following: fast dissolving films, mucoadhesive tablets, hydrogels, intraoral mucoadhesive films, composite wafers, and smart drugs. The novelty elements brought by this paper refer to the possibilities of optimizing the localized drug delivery system in osteoarthritis of the temporomandibular joint, neuropathic pain, oral cancer, periodontitis, and pericoronitis, as well as in maintaining oral health. We would like to mention the possibility of incorporating natural products into the controlled failure systems used in oral pathology, paying special attention to essential oils.

Skin conditions are numerous and often have a major impact on patients’ quality of life, and effective and safe treatment is very important. The conventional drugs used for skin diseases are usually corticosteroids and antimicrobial products that can induce various side effects, especially with long-term use, which is why researchers are studying alternatives, especially biologically active natural products. Three products caught our attention: bee venom (BV), due to reported experimental results showing anti-inflammatory, antibacterial, antiviral, antioxidant, antimycotic, and anticancer effects, Ficus carica (FC) due to its demonstrated antioxidant, antibacterial, and anti-inflammatory action, and finally Geranium essential oil (GEO), with proven antifungal, antibacterial, anti-inflammatory, and antioxidant effects. Following a review of the literature, we produced this paper, which presents a review of the potential therapeutic applications of the three products in combating various skin conditions and for skin care, because BV, FC, and GEO have common pharmacological actions (anti-inflammatory, antibacterial, and antioxidant). We also focused on studying the safety of the topical use of BV, FC, and GEO, and new approaches to this. This paper presents the use of these natural therapeutic agents to treat patients with conditions such as vitiligo, melasma, and melanoma, as well as their use in treating dermatological conditions in patients with diabetes.

Animal venom and plant extracts have been used since ancient times in traditional medicine worldwide. Natural components, valued for their safety and effectiveness, have been consistently used in cosmetic and pharmaceutical applications. We propose a journey along the boulevard of active compounds from natural sources, where bee venom (BV), cobra venom (CV), and Ficus carica reveal their individual therapeutic and cosmetic properties. The originality of this review lies in exploring the synergy of these bioactive sources, an approach that has not been presented in the literature. Although BV, CV, and Ficus carica have different origins and compositions, they have multiple common pharmacological and cosmetic actions, which make them ideal for inclusion in various products that can be used for skin care and health in general. Their anti-inflammatory, antioxidant, immunomodulatory, antimicrobial, neuroprotective, and regenerative properties give them an essential role in the creation of potential innovative and effective products in the pharmaceutical and cosmetics industry. Although many plant extracts have antioxidant and anti-inflammatory properties, Ficus carica was chosen due to its complex biochemical composition, which provides valuable benefits in skin regeneration and protection against oxidative stress. According to the International Nomenclature of Cosmetic Ingredients (INCI), Ficus carica is used in the form of an extract of fruits, leaves, juice, bark or stem, each having specific applicability in topical formulations; due to the diversity of bioactive compounds, it can amplify the effectiveness of BV and CV, helping to enhance their beneficial effects and reducing the risk of adverse effects, due to its well-tolerated nature. Thus, this combination of natural ingredients opens up new perspectives in the development of innovative products, optimizing efficiency and maintaining a favorable safety profile. In this context, due to the reported experimental results, the three natural sources caught our attention, and we conceived the present work, which is a review made following the analysis of the current progress in the study of the bioactive compounds present in BV, CV, and Ficus carica. We focused on the novelties regarding pharmacological and cosmetic actions presented in the literature, and we highlighted the safety profile, as well as the modern approaches regarding the delivery and transport systems of the active substances from the three natural sources, and we evaluated their prospects in therapeutic and cosmetic use. This paper not only expands our knowledge of bioactive compounds, but it can also generate new ideas and motivations for the research and development of innovative treatments and skincare methods.

The present work aimed to create and evaluate some topical pharmaceutical forms with a role in the improvement and treatment of acne. Also, the work aims to characterize the pharmaceutical forms obtained from the point of view of efficiency by determining some physico-chemical and pharmaceutical parameters. The purpose of these determinations is to specify some important aspects with a role in prevention and avoiding recidivism. We created two different pharmaceutical forms, using two concentrations of antibiotic and keratolytic agent, namely, a solution with erythromycin 4% and resorcinol 1% and two creams with erythromycin 1.2% and resorcinol 2% in different emulsion U type ointment bases /A and A/U used in the treatment of acne depending on its stage. Our study followed the macroscopic evaluation of the pharmaceutical forms made, the ph over a period of 30 days, the influence of the ointment bases on the rheological behavior, the satisfaction of the complexity of the treatment on different forms of acne. Microbial contamination is also a quality parameter and was evaluated to observe the behavior of excipients as possible microbial culture media

Periodontitis and dental caries remain among the most prevalent chronic diseases, and their local treatment is limited less by the choice of active agent than by the difficulty of sustaining therapeutic concentrations against salivary and crevicular clearance, the mucosal barrier and the biofilm matrix. This narrative review (PubMed/MEDLINE, Scopus, Web of Science; 2010–2026; 118 sources) maps five mechanistic classes—mucoadhesive, in situ gelling, stimuli-responsive, nano-/microparticulate and biomimetic—alongside marketed sustained-release products onto the specific barrier each addresses and onto an explicit translational gradient. The barriers are quantified rather than described: a pocket of ≈0.5 µL perfused at ≈20 µL/h turns over some 40 times hourly, giving an intra-crevicular half-life of about one minute, and the inflamed pocket is neutral-to-alkaline (pH 7.4–8.5), so acid-triggered release is a cariogenic and not a periodontal strategy, whereas alkaline-triggered release remains an open design space. A dose calculation from these figures identifies payload potency and deliverable mass, not carrier retention, as the binding constraint on phytocompound delivery. Because no single class overcomes all barriers, hybrid nano-in-macro architectures are analysed as the structural solution. Measured against a marketed benchmark of ≈0.3 mm additional probing-depth reduction, progress now depends on consolidation rather than on novelty.